Our data point toward a crucial role of the BRD during differentiation of stem cells, suggesting that in cancer, targeting of BRG1/BRM BRDs may mainly affect cancer stem cell maintenance rather than causing immediate cytotoxicity on tumor cells. This evidence concerns the gene SMARCA2 and cancer.